The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N04 | Anti-parkinson drugs | |
3
|
N04B | Dopaminergic agents | |
4
|
N04BC | Dopamine agonists | |
5
|
N04BC07 | Apomorphine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| PAREN | Parenteral | 20 mg |
| Active Ingredient |
|---|
|
Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites. |
| Document | Type | Information Source | |
|---|---|---|---|
| APO-GO Solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| DACEPTON Solution for infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| KYNMOBI Sublingual film | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.